PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution.
PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida. “We’re joining the fight against COVID-19 by using our ClarityDX technology to rapidly and accurately predict which COVID-19 patients are at risk for developing severe disease” said John Lewis, CEO of Nanostics.
Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.
Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.
Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.
The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic's research into diagnostic testing for prostate cancer.
News Medical Lifesciences - ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.
The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.
1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.
Nanostics' core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.
Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.
NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.
CSO Desmond Pink discusses Nanostics' productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.
Flying with @AirCanada? Pick up En Route magazine and read "19 Canadian Start-ups That Are Out to Change the World." Written by Danielle Groen and illustrated by Martina Paukova.
Global Edmonton Health reporter Su-Ling Goh highlighted 5 amazing medical technologies and treatments from Edmonton research teams and ClarityDX Prostate was one of them!
A local startup with plans to market a more accurate prostate cancer screening test is one of the first businesses to set up shop in a new downtown shared lab space for health tech companies.
Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer.
EDMONTON — Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations...
1.3M North American men get biopsies each year checking for prostate cancer, many of them unnecessary. UofA researchers want to change that with a new test that relies on GPU computing.
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
Alberta men diagnosed with prostate cancer could soon have a better blood test to help determine if they can bypass a painful and invasive biopsy.
The PSA test for prostate cancer has been linked to unnecessary treatments and biopsies. That’s prompted researchers to start developing a more accurate prostate cancer detection tool.
As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.
Author: Desmond Pink, Michael Wong, Diana Pham, Renjith Pillai, Leanne Stifanyk, Sylvia Koch, Rebecca Hiebert, Oliver Kenyon, and John LewisNanoparticle platforms are attractive for theranostic applications due to their multifunctionality and multivalency. Some of the most promising nano-scale scaffolds have been co-opted from nature, such as the cowpea mosaic virus (CPMV). What makes CPMV so promising? They are non-infectious and nontoxic to humans and safe for use in intravital imaging and drug delivery. Click on the link to read more.
Author: Perrin Beatty and John LewisWe are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs (www.APCaRI.ca) robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in the Journal of Clinical Oncology - Clinical Cancer Informatics. Thank you to the Alberta Cancer Foundation and many others for their support.
Author: AUTHOR: MARIA CUTUMISU, CATALINA VASQUEZ, MAXWELL UHLICH, PERRIN H. BEATTY, HOMEIRA HAMAYELI-MEHRABANI, RUME DJEBAH, ALBERT MURTHA, RUSSELL GREINER, AND JOHN D. LEWISThis is a micro-review of an original research article from the Lewis research group that identified multiple novel metastasis-blocking targets, by using a whole genome screen and intravital imaging approach, that could be used as therapeutic targets to inhibit solid tumour cell motility.
Author: Konstantin Stoletov, Lian Willetts, Perrin H. Beatty, and John D. Lewis
CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award.
Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held in Berlin this November. Some travel expenses will be paid for.